DK3912971T3 - Cholinsteraseinhibitorpolymorf og anvendelse deraf - Google Patents

Cholinsteraseinhibitorpolymorf og anvendelse deraf Download PDF

Info

Publication number
DK3912971T3
DK3912971T3 DK20748154.0T DK20748154T DK3912971T3 DK 3912971 T3 DK3912971 T3 DK 3912971T3 DK 20748154 T DK20748154 T DK 20748154T DK 3912971 T3 DK3912971 T3 DK 3912971T3
Authority
DK
Denmark
Prior art keywords
cholinsterase
polymorph
inhibitor
inhibitor polymorph
cholinsterase inhibitor
Prior art date
Application number
DK20748154.0T
Other languages
English (en)
Inventor
Tonghui Wang
Ju Zhang
Lihua Wang
Depu Wang
Yaxin Zhang
Qinghua Yu
Qi Zhang
Mingze Li
Original Assignee
Changchun Huayuan High Science And Tech Co Ltd
Jiangsu Sheneryang High Science And Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Changchun Huayuan High Science And Tech Co Ltd, Jiangsu Sheneryang High Science And Tech Co Ltd filed Critical Changchun Huayuan High Science And Tech Co Ltd
Application granted granted Critical
Publication of DK3912971T3 publication Critical patent/DK3912971T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D219/00Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08Nitrogen atoms
    • C07D219/10Nitrogen atoms attached in position 9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK20748154.0T 2019-01-31 2020-01-21 Cholinsteraseinhibitorpolymorf og anvendelse deraf DK3912971T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910100045 2019-01-31
PCT/CN2020/073389 WO2020156360A1 (zh) 2019-01-31 2020-01-21 胆碱酯酶抑制剂多晶型及其应用

Publications (1)

Publication Number Publication Date
DK3912971T3 true DK3912971T3 (da) 2023-09-04

Family

ID=71841590

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20748154.0T DK3912971T3 (da) 2019-01-31 2020-01-21 Cholinsteraseinhibitorpolymorf og anvendelse deraf

Country Status (8)

Country Link
US (1) US20220227712A1 (da)
EP (1) EP3912971B1 (da)
JP (1) JP7138799B2 (da)
CN (1) CN113166064B (da)
DK (1) DK3912971T3 (da)
ES (1) ES2954408T3 (da)
FI (1) FI3912971T3 (da)
WO (1) WO2020156360A1 (da)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60123290T2 (de) * 2001-03-30 2007-04-05 Council Of Scientific And Industrial Research Ein verfahren zur synthese einer annulierten pyridinbase
CN1239486C (zh) * 2003-02-18 2006-02-01 长春华洋高科技有限公司 吖啶衍生物及其应用
CN109734663B (zh) * 2019-01-31 2020-10-13 长春华洋高科技有限公司 吖啶衍生物的新晶型、制备方法及其应用
CN109651248A (zh) * 2019-01-31 2019-04-19 长春华洋高科技有限公司 琥珀八氢氨吖啶新晶型及其制备方法和用途
CN109796405A (zh) * 2019-01-31 2019-05-24 长春华洋高科技有限公司 琥珀八氢氨吖啶多晶型及其制备方法

Also Published As

Publication number Publication date
ES2954408T3 (es) 2023-11-22
CN113166064B (zh) 2023-04-11
JP7138799B2 (ja) 2022-09-16
JP2022508467A (ja) 2022-01-19
WO2020156360A1 (zh) 2020-08-06
EP3912971B1 (en) 2023-05-31
CN113166064A (zh) 2021-07-23
EP3912971A4 (en) 2022-02-23
FI3912971T3 (fi) 2023-08-21
EP3912971A1 (en) 2021-11-24
US20220227712A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
DK3966207T3 (da) Phenylaminopyrimidinamid-autophagi-hæmmere og fremgangsmåder til anvendelse deraf
DK3966206T3 (da) Heteroarylaminopyrimidinamid-autophagihæmmere og fremgangsmåder til anvendelse deraf
DK3728254T3 (da) Benzylamin-substituerede pyridopyrimidinoner og derivater som sos1-inhibitorer
DK3761980T3 (da) Aminosyreforbindelser og fremgangsmåder til anvendelse
DK3946464T3 (da) Forbindelser og konjugater deraf
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3753937T3 (da) Atr-hæmmer og anvendelse deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3536698T3 (da) Lanosterol-prodrugforbindelse og anvendelse deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3746446T3 (da) PRC2-inhibitorer
DK4084778T3 (da) Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
DK3448955T3 (da) Korrosionshæmmersammensætninger og fremgangsmåder til anvendelse deraf
DK3908570T3 (da) Ketaminpamoat og andevendelse deraf
IL282350A (en) Bernani-RGMC inhibitors and their use
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3677278T3 (da) Isoformselektive tgfbeta1-inhibitorer og anvendelse deraf
DK3426243T3 (da) 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
MA49006A (fr) Inhibiteurs d'ip6k
DK3840837T3 (da) Arginasehæmmere og fremgangsmåder til anvendelse deraf